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Abstract
Purpose Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and thera-
peutic outcomes. The amino acid transporter, SLC7A8, is overexpressed in oestrogen receptor-positive BC. However, the 
consequence of this overexpression, in terms of disease prognosis, is still obscure. This study aimed to evaluate the biological 
and prognostic value of SLC7A8 in BC with emphasis on the intrinsic molecular subtypes.
Methods SLC7A8 was assessed at the genomic, using METABRIC data (n = 1980), and proteomic, using immunohisto-
chemistry and TMA (n = 1562), levels in well-characterised primary BC cohorts. SLC7A8 expression was examined with 
clinicopathological parameters, molecular subtypes, and patient outcome.
Results SLC7A8 mRNA and SLC7A8 protein expression were strongly associated with good prognostic features, including 
small tumour size, low tumour grade, and good Nottingham Prognostic Index (NPI) (all P < 0.05). Expression of SLC7A8 
mRNA was higher in luminal tumours compared to other subtypes (P < 0.001). High expression of SLC7A8 mRNA and 
SLC7A8 protein was associated with good patient outcome (P ≤ 0.001) but only in the low proliferative ER+/luminal A 
tumours (P = 0.01). In multivariate analysis, SLC7A8 mRNA and SLC7A8 protein were independent factors for longer breast 
cancer specific survival (P = 0.01 and P = 0.03), respectively.
Conclusion SLC7A8 appears to play a role in BC and is a marker for favourable prognosis in the most predominant, ER+ 
low proliferative/luminal A, BC subtype. Functional assessment is necessary to reveal the specific role played by SLC7A8 
in ER+ BC.
Keywords SLC7A8 · Breast cancer · Prognosis
Introduction
Many cancer cells alter their metabolism to provide energy 
and cellular building blocks required for their rapid prolif-
eration. Amino acids, particularly glutamine and leucine, 
are essential for cancer cell growth, as they are critical for 
controlling protein translation and driving cell cycle progres-
sion through regulation of the mammalian target of rapamy-
cin complex1 (mTORC1) pathway [1, 2]. This pivotal need 
for intracellular amino acids is reflected in the increased 
expression of amino acid transport systems in the majority 
of cancers, which is regulated by various transcription fac-
tors such as c-MYC, hormone receptors, and nutrient starva-
tion responses [3–5].
Solute Carrier Family 7 Member 8 (SLC7A8) and 
Member 5 (SLC7A5) are sodium-independent amino acid 
exchangers (antiports), which transport small and large 
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neutral amino acids, such as alanine, serine, threonine, 
cysteine, phenylalanine, tyrosine, leucine, and glutamine 
[6]. Both solute carriers require heterodimerisation with the 
heavy chain of SLC3A2 for their proper localisation in the 
plasma membrane [7–9].
Although the function of SLC7A8 and SLC7A5 are simi-
lar, the former displays relatively lower affinity for its sub-
strates, glutamine, and serine. SLC7A5 has been extensively 
studied in a variety of cancers and it is regulated by the 
oncogene c-MYC [10–13]. We have previously described 
the potential utility of SLC7A5 as a poor prognostic factor 
for the highly proliferative breast cancer (BC) subtypes [14]. 
However, there is limited information whether SLC7A8 
plays an equal role in BC. Previous studies showed that 
SLC7A8 is upregulated in ER+BC and it is controlled by 
oestrogen [4, 15]. Luo et al. also identified SLC7A8 as a 
novel progesterone target gene in uterine leiomyoma cells 
[16]. To our knowledge, the prognostic impact of SLC7A8 
has not been studied.
In this study, we aimed to assess SLC7A8 gene copy num-
ber (CN) and mRNA expression, alongside SLC7A8 protein 
expression in large and well-characterised cohorts of BC to 
determine its clinicopathological and prognostic value with 
emphasis on the different molecular classes.
Material and methods
SLC7A8 genomic profiling
SLC7A8 gene copy number and gene expression were 
evaluated using the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) cohort of invasive 
BC (n = 1980) [17]. In this study, DNA/RNA was isolated 
from fresh frozen samples and transcriptional profiling was 
acquired using the Illumina HT-12v3 platforms. Data were 
pre-processed and normalised as described previously [17]. 
Patients involved in the study who were Oestrogen Recep-
tor-negative (ER-) and Lymph Node (LN)-positive received 
adjuvant chemotherapy, while ER+ and/or LN− patients 
did not receive adjuvant chemotherapy. Dichotomisation of 
SLC7A8 mRNA was achieved using X-tile (version 3.6.1, 
Yale University, USA), based on prediction of Breast Cancer 
Specific Survival (BCSS). SLC7A8 mRNA expression was 
associated with clinicopathological parameters, molecular 
subtypes and patient outcome.
The online dataset, Breast Cancer Gene-Expression 
Miner v4.0 (https ://bcgen ex.centr egaud uchea u.fr), was used 
for external validation of SLC7A8 mRNA expression.
SLC7A8 protein expression
Immunhistochemistry for SLC7A8 was performed using a 
well-characterised cohort of early stage primary operable 
invasive BC patients aged ≤ 70 years. Patients presented at 
Nottingham City Hospital between 1989 and 2006. Patients 
were managed based on a uniform protocol. Clinical his-
tory, tumour characteristics, information on therapy, and out-
comes are prospectively maintained. Outcome data included 
development and time to distant metastasis (DM) and BCSS.
Supplementary Table 1 summarises the clinicopathologi-
cal parameters for the Nottingham and METABRIC series.
Western blotting
The specificity of anti-SLC7A8 primary antibody 
(HPA051950, Sigma-Aldrich, UK) was validated using 
Western blotting in BC lysates (American Type Culture 
Collection; Rockville, MD, USA) as previously described 
[18]. A single band for SLC7A8 was visualised at the correct 
predicted size (~ 58 KDa) (Supplementary Fig. 1).
Tissue arrays and Immunohistochemistry (IHC)
Tumour samples, 0.6 mm cores, were arrayed as previously 
described [14, 19]. Immunohistochemical staining was per-
formed on 4 μm TMA sections using Novolink polymer 
detection system (Leica Biosystems, RE7150-K) as per the 
manufacturer’s instructions.
Stained TMA sections were scanned using high resolu-
tion digital images (NanoZoomer; Hamamatsu Photonics, 
Welwyn Garden City, UK), at × 20 magnification. Modi-
fied histochemical score (H-score) was applied to evaluate 
SLC7A8 immunostaining. This includes a semi-quantita-
tive assessment of both the percentage and the intensity of 
stained cells [20]. Staining intensity was graded as: 0, nega-
tive; 1, weak; 2, medium; 3, strong and the percentage of the 
positively stained tumour cells was estimated subjectively. 
The final H-score was calculated multiplying the intensity 
(0–3) by the percentage of positive cells (0–100), producing 
a total range of 0–300. Dichotomisation of SLC7A8 protein 
expression was determined using X-tile software in predict-
ing BCSS.
Immunhistochemical staining and dichotomisation of the 
other biomarkers included in this study were as per previous 
publications [14, 18–22]. ER and PgR positivity was defined 
as ≥ 1% staining. Immunoreactivity of HER2 was scored 
using standard HercepTest guidelines (Dako). Chromogenic 
in situ Hybridisation (CISH) was used to quantify HER2 
gene amplification in borderline cases using the HER2 FISH 
pharmDx™ plus HER2 CISH pharmDx™ kit (Dako) and 
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was assessed according to the American Society of Clinical 
Oncology guidelines. BC molecular subtypes were defined, 
based on tumour IHC profile and the Elston-Ellis [23] 
mitotic score as: ER+/HER2- Low Proliferation (mitotic 
score 1), ER+/HER2− high Proliferation (mitotic score 2 
and 3), HER2− positive class: HER2+ regardless of ER sta-
tus, Triple Negative (TN): ER−, PgR−, and HER2− [24].
Statistical analysis
SPSS 24.0 statistical software (SPSS Inc., Chicago, IL, 
USA) was applied for statistical analysis. The Chi-square test 
was carried out for inter-relationships between categorical 
variables. One-way ANOVA with post hoc Tukey multiple 
comparison test and Pearson’s correlation coefficient was 
performed to analyse the association between continuous 
variables. Survival curves were examined by Kaplan–Meier 
with Log Rank test. Cox’s proportional hazard method was 
performed for multivariate analysis to identify the independ-
ent prognostic/predictive factors. P values were adjusted 
using Bonferroni correction for multiple testing, whenever 
applicable. A P value < 0.05 was considered significant. 
The study endpoints were 10-year BCSS or distant metasta-
sis free survival (DMFS). This study complied with report-
ing recommendations for tumour marker prognostic studies 
(REMARK) criteria [25].
This study was approved by the Nottingham Research 
Ethics Committee 2 under the title ‘Development of a 
molecular genetic classification of breast cancer’ and the 
North West—Greater Manchester Central Research Eth-
ics Committee under the title ‘Nottingham Health Science 
Biobank (NHSB)’ reference number 15/NW/0685.
Results
SLC7A8 in breast cancer
High SLC7A8 mRNA expression was observed in almost 
two-third (67%) of the METABRIC BC cases. A total of 
90/1,980 (4.5%) of cases showed SLC7A8 copy number 
(CN) gain, whereas 45/1,980 (2.3%) cases showed a CN loss. 
A significant association was observed between SLC7A8 
copy number variation (CNV) and SLC7A8 mRNA expres-
sion (P < 0.0001, Fig. 1a). There was a positive association 
between SLC7A8 CN gain and CN gain of the tumour sup-
pressor gene, TP53 (P < 0.0001, Supplementary Table 2).
SLC7A8 protein expression was observed, predominantly 
in the cytoplasm of invasive BC cells, with expression lev-
els varying from absent to high (Fig. 2a and b). Positive 
SLC7A8 protein expression (> 20 H-score) was observed 
in 177/1560 (11%) of cases.
Fig. 1  SLC7A8 mRNA expression and its association with copy 
number aberrations, clinicopathological parameters and molecular 
subtypes: a SLC7A8 and copy number aberrations, b SLC7A8 and 
tumour size, c SLC7A8 and tumour grade, d SLC7A8 and lymph node 
stage, e SLC7A8 and NPI, f SLC7A8 and PAM50 subtypes, g SLC7A8 
and METABRIC Integrative Clusters. Pearson correlation was used 
for two variables and One-way ANOVA with post hoc tukey test for 
more than two variables
 Breast Cancer Research and Treatment
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SLC7A8 and clinicopathological parameters
High SLC7A8 mRNA expression was significantly associ-
ated with good prognostic parameters, including smaller 
tumour size (Fig.  1b, P = 0.007), lower tumour grade 
(Fig.  1c, P < 0.001), and good Nottingham Prognostic 
Index (NPI) (Fig. 1e, P < 0.001). These associations were 
confirmed using the Breast Cancer Gene-Expression Miner 
(Supplementary Fig. 2A–2C).
Similar associations were observed with SLC7A8 pro-
tein expression. Table 1 summarises the observed findings 
between high SLC7A8 protein and good prognostic factors, 
including small tumour size (P = 0.03), low tumour grade 
(P < 0.001), and good NPI (P < 0.001).
SLC7A8 expression in molecular BC subtypes
High expression of SLC7A8 mRNA was significantly associ-
ated with hormone receptor positive (ER+ and PgR+) and 
HER2− BC (all P < 0.001, Table 2). Likewise, SLC7A8 
mRNA was highly expressed in non-triple negative (TN) 
compared with TN tumours (P < 0.001, Table 2). These 
results were validated using Breast Cancer Gene-Expres-
sion Miner (Supplementary Fig 2D–2G). Similarly, high 
SLC7A8 protein expression was associated with HER2 
negative BC (P = 0.01) and although it was expressed pri-
marily in hormone receptor positive tumours this did not 
reach significance (Table 2).
Regarding the association of SLC7A8 CN and mRNA 
with the intrinsic (PAM50) subtypes, SLC7A8 CN gain was 
mainly observed in luminal B tumours (P < 0.001, Sup-
plementary Table 2), whereas high mRNA expression was 
observed primarily in luminal A and B tumours and to lesser 
extent in HER2+BC (P < 0.001, Fig. 1f). In the META-
BRIC Integrative Clusters, high SLC7A8 mRNA expression 
was associated with clusters 7 and 8 which embrace ER+ 
tumours predominately of the luminal A intrinsic subtype 
(P < 0.001, Fig. 1g). Similar associations of SLC7A8 mRNA 
with the molecular subtypes were seen using Breast Cancer 
Gene-Expression Miner (Supplementary Fig. 2H).
Although the result of the association of SLC7A8 protein 
in the defined IHC subtypes were not nominally significant, 
it also showed higher SLC7A8 expression in the ER+ low 
proliferation tumours compared with the other subtypes 
(Table 1).
SLC7A8 expression and other associated 
markers
The correlations of SLC7A8 mRNA with other relevant 
genes were investigated using the METABRIC dataset 
(Table 3). These genes were selected based on previous pub-
lications showing a functional association between SLC7A8 
and glutamine transport or metabolism [6, 26–28]. High 
SLC7A8 mRNA expression was significantly associated 
with enzymes involved in glutamine metabolism: glutami-
nase (GLS and GLS2; P < 0.001), which mediate the conver-
sion of glutamine to glutamate. While the correlation with 
GLS was negative, it was positive with GLS2. There was 
also a positive association with the enzymes which medi-
ate conversion of glutamine to proline, namely, ALDH4A1 
and PRODH (P < 0.001). In contrast, some glutamine trans-
porters were negatively correlated with SLC7A8 expres-
sion (P ≤ 0.009), including SLC1A5, SLC7A5, SLC7A6, 
SLC7A7, and SLC38A3, while others showed a positive 
association, including SLC7A9, SLC38A1, SLC38A2, and 
SLC38A7 (P ≤ 0.003). The associations between SLC7A8 
and glutamine metabolic enzymes and transporters were 
primarily observed within luminal A tumours and to lesser 
extent in luminal B, HER2+ and TN subtypes. High SLC7A8 
mRNA expression was associated with tumours which 
showed wild-type TP53 expression (P < 0.001, Table 3).
Fig. 2  SLC7A8 protein expres-
sion in invasive breast cancer 
cores. a Positive IHC expres-
sion, b negative IHC expression
Breast Cancer Research and Treatment 
1 3
SLC7A8 protein was significantly expressed with high 
GLS and GLS2 enzymes (P < 0.001 and P = 0.006, Table 4), 
respectively. High PRODH, ALDH18A1, and ALDH4A1 
were expressed in breast tumours with high SLC7A8 expres-
sion (all P ≤ 0.004, Table 4). High SLC7A8 expression was 
associated with low levels of SLC7A5 (P < 0.03, Table 4), 
whereas paradoxical associations were observed with the 
other transporters, SLC38A2 and SLC7A11 (P ≤ 0.02, 
Table 4).
SLC7A8 expression and patient outcome
High expression of SLC7A8 mRNA and protein was associ-
ated with longer BCSS (P ≤ 0.001, Figs. 3a and 4a). While 
SLC7A8 mRNA expression was not predictive for BCSS in 
any specific molecular class (Fig. 3b–e), high expression of 
SLC7A8 protein was predictive of good survival in only the 
ER + low proliferation tumours (P = 0.01, Fig. 4b). There 
was no association between SLC7A8 protein and outcome in 
ER+ high proliferation, HER2+ or TN subtypes (Fig. 4c–e). 
Multivariate Cox regression analysis showed that SLC7A8 
mRNA and SLC7A8 protein were predictors of longer BCSS 
independent of tumour size, grade, and lymph node stage 
(P = 0.01 and P = 0.03, Table 5) respectively.
Likewise, high SLC7A8 protein expression was associ-
ated with longer distant metastases-free survival (DMFS) 
(P < 0.001, Supplementary Fig. 3A) within the ER+ low 
proliferation class (P = 0.003, Supplementary Fig. 3B) but 
not with other subtypes (Supplementary Fig. 3C, 2E). The 
relationship between high SLC7A8 mRNA expression and 
good patient outcome was verified using Breast Cancer 
Gene-Expression Miner (Supplementary Fig. 4A, 4B).
Discussion
BC represents a group of heterogeneous diseases that vary 
at the histopathological and molecular levels. These sub-
types differ in their biology, clinical outcome, and response 
to therapy [29]. In addition, different BC subtypes showed 
Table 1  Clinicopathological 
associations of the SLC7A8 
protein expression in breast 
cancer
Bold indicates the significant values
Parameter SLC7A8 protein χ2 (P value) Adjusted P value
Low
n (%)
High
n (%)
Tumour size
 < 2 cm 756 (87.1) 112 (12.9) 7.03 (0.008) 0.03
 ≥ 2 cm 623 (91.3) 59 (8.7)
Tumour grade
 1 182 (82.7) 38 (17.3) 20.62 (0.00003) 0.0002
 2 491 (86.7) 75 (13.3)
 3 704 (92.4) 58 (7.6)
Lymph node stage
 1 840 (87.9) 116 (12.1) 4.84 (0.08) 0.16
 2 400 (89.7) 46 (10.3)
 3 136 (93.8) 9 (6.2)
Nottingham Prognostic Index
 Good 397 (83.8) 77 (16.2) 20.09 (0.00004) 0.0002
 Moderate 746 (90.6) 77 (9.4)
 Poor 234 (93.2) 17 (6.8)
IHC subtypes
 ER+/HER2− low proliferation 706 (87.7) 99 (12.3)
 ER+/HER2− high proliferation 230 (90.9) 23 (9.1) 5.67
 Triple negative 207 (88.5) 27 (11.5) (0.128) 0.24
 HER2+ 145 (93.5) 10 (6.5)
Histological type
 Ductal (including mixed) 1217 (89.6) 142 (10.4)
 Lobular 88 (87.1) 13 (12.9) 15.93
 Medullary 23 (92.0) 2 (8.0) (0.01) 0.03
 Miscellaneous 7 (77.8) 2 (22.2)
 Special type 41 (78.8) 11 (21.2)
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disparity in their metabolic profiles and nutritional require-
ments. ER+/luminal tumours are the predominant BC sub-
type [30, 31] and characterised by having better prognosis 
and lower mortality rates as well as being targets for endo-
crine therapy [32]. In clinical practice, however, recognising 
patients who are likely to exhibit relapse or distant metasta-
sis is challenging. Therefore, understanding the biology of 
BC is crucial in the pursuit of identifying targets for treat-
ment and/or prognosis of BC patients particularly those with 
luminal tumours.
Altered metabolic pathways in human cancers are impera-
tive to support cell proliferation and survival. Amino acid 
metabolism can vary substantially among BC subtypes, 
where TNBC display increased activity of amino acid con-
sumption and metabolism compared with ER+ tumours 
[33, 34], suggesting that the latter subtype may allow for 
expression of lower levels of amino acid metabolic markers 
or express solute carriers that have lower affinity for their 
substrates. This study has revealed, for the first time, that 
SLC7A8 is a key amino acid transporter in the most pre-
dominant low proliferative ER+ tumours.
Unlike SLC7A5, SLC7A8 lacks studies that illustrate 
its prognostic role in human cancer. Data from Oncomine 
revealed a significant upregulation of SLC7A8 in several 
cancers, including breast, colorectal, head and neck, leu-
kaemia, lymphoma, and melanoma [35]. However, this 
only has been validated at the mRNA level in a subset of 
breast tumours [15] and melanoma cell lines, which showed 
however more than five times increase in SLC7A5 expres-
sion compared to SLC7A8 [36]. Herein, we used large BC 
cohorts to reveal the significant associations between the 
high SLC7A8 expression, at mRNA and protein levels, and 
good prognostic clinicopathological parameters, including 
small tumour size, low tumour grade, and good NPI.
With respect to BC subtypes, the lowest levels of SLC7A8 
mRNA were observed in the ER- and TNBC tumours, while 
SLC7A8 was higher in the ER+ subtypes which was more 
prominent in the luminal A tumours. These results were 
compatible with other studies which showed that SLC7A8 
mRNA was expressed in the ER+, MCF7, cell line but not 
in the ER−, MDA-MB-231 cells [37]. Furthermore, we 
have shown that SLC7A8 was associated with better patient 
outcome and longer DMFS in the ER+ low proliferative 
tumours only and not in the other subtypes. Thakkar et al. 
also found that upregulation of SLC7A8 alongside GATA3 
and MLPH significantly associated with longer relapse 
free survival in ER+ lymph node positive breast tumours 
[15]. These results may suggest that ER+ low proliferative 
tumours settle for the lower affinity transporter, SLC7A8, to 
satisfy their nutritional needs as they exhibit lower metabolic 
activity compared to the aggressive forms of BC.
Table 2  Expression of SLC7A8 in breast cancer and the expression of other molecular biomarkers
Bold indicates the significant values
SLC7A8
mRNA protein
Low
n (%)
High
n (%)
χ2 (P value) Adjusted
P value
Low
n (%)
High
n (%)
χ2 (P value) Adjusted
P value
ER
 Negative 365 (77.2) 108 (22.8) 553.2 (2.5 × 10–122)  < 0.0001 296 (89.4) 35 (10.6) 0.09 (0.76) 1.52
Positive 283 (18.9) 1215 (81.1) 1083 (88.8) 136 (11.2)
PR
 Negative 453 (48.3) 484 (51.7) 193.6 (5.0 × 10–44)  < 0.0001 559 (91.0) 55 (9.0) 3.53 (0.06) 0.30
Positive 195 (18.9) 839 (81.1) 807 (88.0) 110 (12.0)
HER2
 Negative 519 (30.1) 1206 (69.9) 48.7 (2.9 × 10–12)  < 0.0001 1174 (88.3) 155 (11.7) 8.82 (0.003) 0.01
 Positive 129 (52.4) 117 (47.6) 198 (95.2) 10 (4.8)
Triple negative
 No 388 (23.5) 1263 (76.5) 405.07 (4.3 × 10–90)  < 0.0001 1169 (89.4) 139 (10.6) 0.56 (0.45) 1.80
 Yes 260 (81.3) 60 (18.8) 207 (87.7) 29 (12.3)
TP53 mutations
 Wild-type 204 (28.5) 512 (71.5) 38.36 (4.6 × 10–9)  < 0.0001 Not available
 Mutation 59 (59.6) 40 (40.4)
p53 protein
 Negative Not available 860 (89.0) 106 (11.0) 0.24 (0.62) 1.86
 Positive 435 (89.9) 49 (10.1)
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The relationship between hormone receptor positivity 
and SLC7A8 indicate that hormone receptors have a possible 
role in stimulating SLC7A8 expression. It has been shown 
that 17β estradiol, in ER+ BC cells, regulates l-leucine 
uptake through SLC7A5 and SLC7A8 while no effect was 
observed in the ER- BC cells [4]. It has been further shown 
that SLC7A8 has oestrogen-dependent expression, in ER+ 
BC cells, and the existence of inhibitors of oestrogen sig-
nalling pathway (ICI182780 and tamoxifen) eliminates the 
oestrogen-induced upregulation of SLC7A8 [15]. Another 
study also revealed that progesterone significantly upreg-
ulates SLC7A8 mRNA and SLC7A8 protein expressions, 
in uterine leiomyoma tissues, and knockdown of SLC7A8 
markedly increased leiomyoma cell proliferation [16].
P53 is a well-known tumour suppressor gene that 
responds to various stress signals through modulating other 
cellular processes, including cell cycle arrest and apoptosis. 
P53 also has a role in mediating other cellular mechanisms 
such as regulating metabolic pathways, including glutamine 
metabolism by inducing GLS2 expression [38]. Interestingly, 
this study showed a positive association between wild-type 
P53 and SLC7A8. This suggests that SLC7A8 may contrib-
ute to P53-dependent tumour suppression, which resulted in 
the presence of favourable prognosis and patient outcome 
in tumours expressing high SLC7A8. In addition, SLC7A8 
was upregulated alongside two tumour suppressor genes, 
CEACAM1 and BMP2, in human colon cancer cells after 
exposure to anti-tumour agent [39].
We have previously showed that SLC7A5 is highly 
expressed in the aggressive BC subtypes and it was predic-
tive of poor prognosis and poor patient outcome [14] while 
analysing SLC7A8 in the same cohort has resulted in oppo-
site findings. Furthermore, this study showed that SLC7A8 
at both mRNA and protein levels were mutually exclusive 
with SLC7A5 expression. It is noteworthy that although 
SLC7A5 and SLC7A8 have similar substrate selectivity and 
function, the latter has narrower tissue expression pattern 
and exhibits lower affinity to its substrates [6]. There is also 
evidence which suggests that the role of SLC7A8 is limited 
to equilibration of amino acids distribution across the cell 
membrane while SLC7A5 mediates the actual net of amino 
acid flux [40], which is required for further mTORC1 activa-
tion and cellular proliferation.
Furthermore, it seems that both solute carriers have con-
trasting effect in tumourigenesis and they could be a subject 
of different regulatory mechanisms, as SLC7A5 expression 
is induced by c-MYC while hormone receptors appear to 
control SLC7A8 expression [4, 14, 16].
This study further investigated the association of SLC7A8 
expression with other solute carriers which involved in amino 
acid transport. While the majority of these transporters were 
negatively associated with SLC7A8, others were positively 
correlated, including SLC38A7 which showed consistent cor-
relation in all BC subtypes. Positive associations with sev-
eral glutamine metabolic enzymes were also detected, among 
these, GLS2 and glutamate dehydrogenase (GLUD1) which 
are associated with tumours of good prognosis and favourable 
patient outcome [21, 41]. Some variability in the expression of 
investigated markers across molecular subtypes was observed. 
For example, luminal A tumours were the main class which 
showed association between SLC7A8 and markers required for 
glutamine transport and metabolism. This could be attributed 
to the increased SLC7A8 expression and function in this par-
ticular BC subtype.
It is noteworthy that different transcriptional pathways 
such as c-MYC oncogenic transcription, hormone receptors 
and nutrient starvation responses regulate the expression of 
amino acid transporters in human cancers [27, 35]. This also 
applies to SLC7A5 and SLC7A8, as both belong to the sys-
tem L transport family but their expression is controlled by 
Table 4  Association between SLC7A8 protein expression and other 
biomarkers
SlC7A8 protein
Low, n (%) High, n (%) χ2 (P value)
PRODH
 Negative 255 (89.8) 29 (10.2) 10.93 (0.001)
 Positive 46 (74.2) 16 (25.8)
GLS
 Negative 226 (92.6) 18 (7.4) 18.45 (0.00001)
 Positive 118 (77.6) 34 (22.4)
GLS2
 Negative 171 (89.5) 20 (10.5) 7.41 (0.006)
 Positive 155 (79.5) 40 (20.5)
ALDH18A1
 Negative 190 (91.8) 17 (8.2) 8.17 (0.004)
 Positive 157 (82.2) 34 (17.8)
ALDH4A1
 Negative 185 (92.0) 16 (8.0) 11.19 (0.001)
 Positive 152 (80.4) 37 (19.6)
 Positive
SLC7A5
 Negative 1040 (88.1) 140 (11.9) 4.66 (0.03)
 Positive 253 (92.7) 20 (7.3)
SLC38A2
 Negative 992 (89.5) 116 (10.5) 10.21 (0.001)
 Positive 89 (79.5) 23 (20.5)
SLC7A11
 Negative 465 (92.1) 40 (7.9) 4.84 (0.02)
 Positive 580 (88.1) 78 (11.9)
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Fig. 3  SLC7A8 mRNA and breast cancer patient outcome. a SLC7A8 vs BCSS in all cases, b SLC7A8 vs BCSS in luminal A tumours, c SLC7A8 
vs BCSS in Luminal B tumours, d SLC7A8 vs BCSS in HER2+ tumours, e SLC7A8 vs BCSS in Triple Negative tumours
Fig. 4  SLC7A8 protein and breast cancer patient outcome. a 
SLC7A8 vs BCSS in all cases, b SLC7A8 vs BCSS of ER+—low 
proliferation tumours, c SLC7A8 vs BCSS of ER+—high Prolifera-
tion tumours, d SLC7A8 vs BCSS of HER2+ tumours, e SLC7A8 vs 
BCSS of Triple Negative tumours
 Breast Cancer Research and Treatment
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different pathways. Furthermore, both solute carriers mediate 
the uptake of large neutral amino acids, with the latter showing 
decreased transporting capacity. However, SLC7A8 can also 
accept smaller neutral amino acids, such as glycine, alanine, 
serine, cysteine, and glutamine [42], which are known sub-
strates of the key system A amino acid transporter, SLC1A5 
that is highly expressed in TNBC [6, 43]. These statements 
indicate that SLC7A8 could be a key transporter in luminal A 
tumours through determining the actual net flux of not only 
the large but also the small neutral amino acids.
Conclusion
This study has revealed that the solute carrier SLC7A8 
is an independent good prognostic marker in BC. Over-
expression of SLC7A8 appears to have tumour suppres-
sive characteristics especially in the low proliferative ER+ 
subtype, thus it could act as a potential prognostic factor. 
Functional assessment is necessary to reveal the specific 
role played by this amino acid transporter in the low pro-
liferative ER+ tumours.
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